Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients

@article{Sekino2019ProtocadherinBP,
  title={Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients},
  author={Yohei Sekino and N. Oue and S. Mukai and Y. Shigematsu and Keisuke Goto and N. Sakamoto and K. Sentani and T. Hayashi and J. Teishima and A. Matsubara and W. Yasui},
  journal={The Prostate},
  year={2019},
  volume={79},
  pages={234 - 242}
}
  • Yohei Sekino, N. Oue, +8 authors W. Yasui
  • Published 2019
  • Biology, Medicine
  • The Prostate
  • Background Prostate cancer (PCa) is a common malignancy worldwide and is the second leading cause of cancer death in men. The standard therapy for advanced PCa is androgen deprivation therapy (ADT). Although ADT, including bicalutamide treatment, is initially effective, resistance to bicalutamide frequently occurs and leads to the development of castration‐resistant PCa. Thus, clarifying the mechanisms of bicalutamide resistance is urgently needed. We designed this study to assess the… CONTINUE READING
    9 Citations
    KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer
    • 9
    • PDF
    TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
    • 14
    • PDF
    Protocadherins at the Crossroad of Signaling Pathways
    • 1
    • PDF
    Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells
    • 10

    References

    SHOWING 1-10 OF 45 REFERENCES
    Structural basis for antagonism and resistance of bicalutamide in prostate cancer
    • 317
    • PDF
    Protocadherin‐PC promotes androgen‐independent prostate cancer cell growth
    • 26
    Overexpression of PCDHB9 promotes peritoneal metastasis and correlates with poor prognosis in patients with gastric cancer
    • 13
    Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer
    • 31
    • PDF
    The Epigenetic promise for prostate cancer diagnosis
    • 123